MedTrace Logo

Axitinib as Maintenance Treatment in Patients With Metastatic CRC

NCT01483638 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the maintenance therapy with axitinib in patients with metastatic colorectal carcinoma

Conditions

  • Colorectal Carcinoma

Interventions

DRUG

axitinib

5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.

DRUG

placebo

will be administered orally with the same schedule of axitinib

Sponsors & Collaborators

  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    lead OTHER

Principal Investigators

  • Cristina Grávalos, MD · Hospital 12 de Octubre

  • Alfredo Carrato, MD, PhD · Hospital Universitario Ramon y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01483638 on ClinicalTrials.gov